Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Phenylbutazone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 2/20 | 0.80 |
| ▸ | RAB9A | P51151 | 3/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.80 |
| ▸ | LMNA | P02545 | 2/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.80 |
| ▸ | TP53 | P04637 | 1/20 | 0.80 |
| ▸ | MAPT | P10636 | 1/20 | 0.80 |
| ▸ | HPGD | P15428 | 1/20 | 0.80 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.80 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.51 |
| ▸ | GRM2 | Q14416 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenylbutazone SCHEMBL3632 | 0.98 | RAB9A (0.82) | RAB9AALDH1A1CYP3A4LMNAPTGS1 | |
| Phenylbutazone SCHEMBL8005041 | 0.98 | RAB9A (0.82) | RAB9AALDH1A1CYP3A4LMNAPTGS1 | |
| Phenylbutazone SCHEMBL10913190 | 0.97 | RAB9A (0.80) | RAB9AALDH1A1CYP3A4LMNAPTGS1 | |
| Phenylbutazone SCHEMBL7715162 | 0.97 | RAB9A (0.80) | RAB9AALDH1A1CYP3A4LMNAPTGS1 | |
| Phenylbutazone SCHEMBL21694456 | 0.97 | RAB9A (0.80) | RAB9AALDH1A1CYP3A4LMNAPTGS1 | |
| Phenylbutazone SCHEMBL2122724 | 0.97 | RAB9A (0.80) | RAB9AALDH1A1CYP3A4LMNAPTGS1 | |
| SCHEMBL29489697 | 0.92 | ALDH1A1 (0.73) | RAB9AALDH1A1CYP3A4LMNAPTGS1 | |
| Oxyphenbutazone Anhydrous SCHEMBL1263248 | 0.91 | LMNA (0.97) | RAB9AALDH1A1CYP3A4LMNAPTGS1 | |
| Phenylbutazone SCHEMBL11269971 | 0.91 | ALDH1A1 (0.72) | RAB9AALDH1A1CYP3A4LMNAPTGS1 | |
| Oxyphenbutazone Anhydrous SCHEMBL1263243 | 0.90 | LMNA (0.94) | RAB9AALDH1A1CYP3A4LMNAPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118141602-A | Lacrimal canaliculus embolism | 上海曙瑞科技有限公司 | 2024-06-07 | — | — | CN | claimed |
| WO-2010097643-A1 | FORMULATION BASED ON MICRONIZED ZEOLITE, GREEN TEA EXTRACT, AND GENISTEIN AS A THERAPEUTIC AGENT FOR REDUCTION OF BODY WEIGHT AND CELLULITE | NOVATECH ISTRAZIVANJE D.O.O. (HR) | 2010-09-02 | — | — | WO | claimed |
| WO-2010018418-A1 | FORMULATION BASED ON MICRONIZED CLINOPTILOLITE AS THERAPEUTIC AGENT PROVIDING HIGHLY BIOAVAILABLE SILICON | NOVATECH D.O.O. (HR) | 2010-02-18 | — | — | WO | claimed |
| US-12221524-B2 | Polymerization initiator, curable composition, dental material, and preparation kit for curable composition | MITSUI CHEMICALS, INC. (JP) | 2025-02-11 | — | — | US | disclosed |
| CN-118450890-A | Treatment of cancer and autoimmune disorders using nano-polymers of histone deacetylase inhibitors | 弗吉尼亚大学专利基金委员会 | 2024-08-06 | — | — | CN | disclosed |
| CN-118141602-A | Lacrimal canaliculus embolism | 上海曙瑞科技有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-118139614-A | Sterile liposome-containing compositions and articles | 脂肪球有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-111527065-B | Synthetic derivatives of oleoyl-lysophosphatidylinositol (oleoyl-LPI) and uses thereof | 科廷大学 | 2024-05-07 | — | — | CN | disclosed |
| EP-3835329-B1 | POLYMERIZATION INITIATOR, CURABLE COMPOSITION, DENTAL MATERIAL, AND PREPARATION KIT FOR CURABLE COMPOSITION | MITSUI CHEMICALS INC (JP) | 2024-05-01 | — | — | EP | disclosed |
| CN-112920092-B | Prodrugs of glutamine analogues | 约翰霍普金斯大学 | 2024-04-26 | — | — | CN | disclosed |
| CN-110678543-B | In vitro culture system and method of use thereof | 耶达研究及发展有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-105272368-A | Waterproof agent for ceramic building | YANTAI SHUNLONG CHEMICAL SCIENCE & TECHNOLOGY CO LTD | 2016-01-27 | — | — | CN | disclosed |
| WO-2010097643-A1 | FORMULATION BASED ON MICRONIZED ZEOLITE, GREEN TEA EXTRACT, AND GENISTEIN AS A THERAPEUTIC AGENT FOR REDUCTION OF BODY WEIGHT AND CELLULITE | NOVATECH ISTRAZIVANJE D.O.O. (HR) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010018418-A1 | FORMULATION BASED ON MICRONIZED CLINOPTILOLITE AS THERAPEUTIC AGENT PROVIDING HIGHLY BIOAVAILABLE SILICON | NOVATECH D.O.O. (HR) | 2010-02-18 | — | — | WO | disclosed |
| EP-1981343-A2 | TREATMENT OF INFLAMMATORY DISORDERS WITH TRIAZOLE COMPOUNDS | Barrier Therapeutics, Inc. (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1448220-B1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ANTIPHLOGISTIC AGENT AND LACTALBUMINHYDROLYSATE AND THE USE THEREOF | EXALATION LTD (GB) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007084542-A2 | TREATMENT OF INFLAMMATORY DISORDERS WITH TRIAZOLE COMPOUNDS | BARRIER THERAPEUTICS, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
| US-20050054556-A1 | Antiphlogistic agent and the use thereof | KOSMAS KG (DE) | 2005-03-10 | — | — | US | disclosed |
| EP-1448220-A2 | ANTIPHLOGISTIC AGENT AND THE USE THEREOF | Kosmas KG (DE) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003045416-A2 | ANTIPHLOGISTIC AGENT AND THE USE THEREOF | KOSMAS KG (DE) | 2003-06-05 | — | — | WO | disclosed |